Dihexa
Overview
Dihexa is a small synthetic hexapeptide derived from angiotensin IV, designed to bind and potentiate hepatocyte growth factor (HGF) signaling through the c-Met receptor. This action is hypothesized to promote synaptogenesis, dendritic spine formation, and neuronal survival in models of cognitive impairment.
Mechanism of Action
Dihexa exhibits high oral bioavailability and blood-brain barrier penetration due to its small size and lipophilic character..
Research Summary & Key Findings
Preclinical studies in rodent models of Alzheimer disease and traumatic brain injury have demonstrated improvements in spatial learning and memory consolidation. No human clinical trials have been published in peer-reviewed journals, and safety and efficacy data in humans remain absent.
Clinical Status
Dihexa is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
Related Peptides in Cognitive
Semax
FDA ApprovedA synthetic heptapeptide analog of the ACTH(4-7) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with nootropic and neuroprotecti...
View detailsSelank
InvestigationalA synthetic analog of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence for stabi...
View detailsCerebrolysin
InvestigationalA porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids that m...
View detailsP21 (Peptide)
Research PhaseA small synthetic peptide derived from the active region of ciliary neurotrophic factor (CNTF) designed to promote neuro...
View detailsFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Dihexa.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.